Source Seven L, medsci
Metabolic syndrome (Mets) is coming to the forefront globally and is widely believed to contribute to an increased risk of several cancers, such as urothelial carcinoma of the bladder (UCB). Researchers conducted a study to assess the relationship between Mets and UCB.
The investigators conducted a case-control study of 690 cancer patients and 665 non-cancer matched patients in Italy between 2003 and 2014. mets should fit at least 3 of the following: abdominal obesity, hypercholesterolemia, hypertension and diabetes. Multifactorial logistic regression models estimated ORs and 95% confidence intervals (CIs) between Mets and UCB’s after correction for potential confounders.
The study data showed a 2-fold increased risk of UCB in Mets compared with non-Mets patients (95 % CI: 1.38-3.19). Bladder cancer risk OR=2.20 (95 % CI: 1.42-3.38) in patients with diabetes, OR=0.88 (95 % CI: 0.66-1.17) in patients with hypertension and OR=1.16 (95 % CI: 0.80-1.67) in patients with hypercholesterolemia.
The risk of bladder cancer in patients with abdominal obesity was OR=1.63 (95 % CI: 1.22-2.19). There was no heterogeneity between the case and control groups in terms of gender, age, education, geographic area, and smoking habits. Overall 8.1 % (95 % CI: 3.9-12.4 %) of UCB cases were attributed to Mets.
The results of this study support previous studies that Mets increases the risk of bladder cancer.
Original source.
Montella M, Di Maso M,et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study.BMC Cancer. 2015 Oct 16;15:720.
?